ASCEND
04 May 2022
Trial Summary
A Randomised, double-blinded phase II study of gemcitabine and nab‐paclitaxel with CEND‐1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.
Acronym:
ASCEND
ACTRN/NCT /ethics:
NCT05042128
Scientific title:
The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)
Sponsor / Cooperative group:
Australasian Gastro-Intestinal Trials Group
Trial & Patient Characteristics
| Cancer Type | Pancreas |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2022-04-13 |
| Anticipated End Date | 2024-10-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| stella.papacharissiou@sa.gov.au | |
| Phone | 08 8222 6410 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Recruiting |
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Chris Karapetis |
| Recruitment Status | Recruiting |